Pharma Focus Asia

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership to Commercialize VAZKEPA®

Tuesday, August 01, 2023

Amarin Corporation and Lotus Pharmaceuticals have entered into significant long-term exclusive partnership to distribute and commercialise VAZKEPA® (icosapent ethyl) in ten countries. 

As per the agreement between Amarin Corporation and Lotus Pharmaceuticals, Lotus will have exclusive rights to distribute and carry out commercial promotion for VAZKEPA® in South Korea and nine countries within the Association of Southeast Asian Nations (ASEAN). These countries include Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.

Under the terms of agreement, Amarin Corporation will receive an upfront payment, pricing and reimbursement benefits, and sales milestone payments. These payments will be based on the net sales of VAZKEPA® in the regions covered by the agreement.

VAZKEPA® capsules have received approval and have been successfully commercialised in various markets, including the United States and European countries as the first prescription treatment comprised solely of the active ingredient icosapent ethyl, which is a highly purified form of eicosapentaenoic acid (EPA).

This partnership agreement aims to bring innovative and transformative treatments to patients.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024